Table 3.
Univariate and multivariate analysis for melanoma patients with liver metastasis receiving cryoablation and PD-1 blockade combination treatment (n = 45)
| Category | n | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (> 53/ ≤ 53) | 20/25 | 0.85 (0.34–2.13) | 0.725 | – | – |
| Sex (female/male) | 26/19 | 0.96 (0.38–2.40) | 0.926 | – | – |
| Tumor origin (other/cutaneous) | 30/15 | 1.47 (0.53–4.09) | 0.463 | – | – |
| Number of metastatic sites (> 2/ ≤ 2) | 13/32 | 2.93 (1.17–7.32) | 0.022 | 3.54 (1.32–9.49) | 0.012 |
| Diameter of intrahepatic tumor (> 30/ ≤ 30) | 20/25 | 2.60 (1.03–6.59) | 0.044 | – | – |
| Diameter of intrahepatic tumor (> 50/ ≤ 50) | 7/38 | 1.15 (0.33–4.06) | 0.826 | – | – |
| Number of intrahepatic metastases (> 3/ ≤ 3) | 35/10 | 1.66 (0.48–5.74) | 0.423 | – | – |
| LDH level (> 300 U/L/ ≤ 300 U/L) | 15/30 | 4.87 (1.94–12.21) | 0.001 | 4.59 (1.78–11.85) | 0.002 |
| Diameter of ablated lesion (> 30/ ≤ 30 mm) | 15/30 | 3.40 (1.26–9.18) | 0.016 | 3.27 (1.17–9.15) | 0.024 |
| Time from liver metastasis to cryoablation (> 0.5/ ≤ 0.5 months) | 28/17 | 2.87 (0.95–8.69) | 0.062 | – | – |
| Anti-angiogenic agents (present/absent) | 8/37 | 0.92 (0.21–4.01) | 0.921 | – | – |
| Chemotherapy (present/absent) | 6/39 | 1.10 (0.32–3.80) | 0.875 | – | – |
| NLR (> 2.8/ ≤ 2.8) | 28/17 | 2.78 (1.11–6.94) | 0.029 | – | – |
| CD16 + CD56 + cells (> 20%/ ≤ 20%)Ѱ | 17/17 | 0.25 (0.08–0.81) | 0.021 | / | / |
| CD4 + CD25 + cells (> 23%/ ≤ 23%)Ѱ | 7/27 | 4.47 (1.40–14.28) | 0.011 | / | / |
ѰThe pre-treatment percentage of CD3-CD16 + CD56 + cells and CD4 + CD25 + cells among immune cells were not included in the multivariate analysis due to the missing values of more than 20% among all the included patients